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Detection of Multiple Polycyclic Aromatic
Hydrocarbon-DNA Adducts by a High-
Performance Liquid Chromatography-
32P-Postlabeling Method
by NancyJ. Gorelick and Nancy L. Reeder
A32P-postlabeling procedureforidentifyingandquantifying hydrophobicDNAadductswasdeveloped (by modifying
the method of Randerath and co-workers) in which labeled adducts are separated by high-performance liquid
chromatogaplhy(PLC)andquantified byliqudsciiati ontinag Thismethodwasfirstdevelopedforfluoranthene-
DNAadducts, andmethodsforoptimaldetectionandquant ofDNAadductswithdidepoxdemetabolitesofben-
zolaJpyrene (BPDE), chrysene(CHDE), andbenz[aJanthracene (BADE) havenow beenestablished. Analyticalcondi-
tions slightly different from those adopted for fluoranthene-DNA adductsare required foraccurate quantification of
BPDE-, CHDE-, and BADE-DNA adducts. In particular, HPLC analysis requires generation of nucleotide
5'-[I PmonophosphateadducesbytreatmentwithnucleaseP1,andpolyclicaromatichydrocarbonadductsdemonstrate
variable sensitivity tonucleasePI, mediated dephosphorylation. Thus, multipleadductscanbedetectedinonesample
aslongastherecovery ofadductsundertheappliedconditionshasbeendeterminedandchromatographicseparationof
labeledadductsisachieved. Abattery ofpostlabelingassayscanthusmakeit possibletodetectoptimally multipleadducts
inoneDNAsample. ResultsfromthesestudiesindicatethattheHPLC-'P-postlabelingassayiscomplementary toim-
munoassaysinwhich relatedpolycyclicaromatichydrocarbondiolepoxideadductscross-reactforthequantification of
adducts.
Introduction
Interspecies and interindividual variability in response to
chemical carcinogens may beattributable inpart todifferences
in the dose delivered to the target site. Many carcinogens bind
covalently toDNA, andthis DNAmodification isthoughttobe
a key initial event in mutagenesis and carcinogenesis. Thus,
carcinogen-DNAadductsmaybebiologically importantmarkers
ofthe delivered dose.
Postlabeling assays are useful for quantifying DNA adducts
formed in vivo. Recently, aversionofthe "P-postlabeling pro-
cedure in which high-performance liquid chromatography
(HPLC), instead of thin-layer chromatography, is used for
separation oflabeledadducts wasdescribed (1). Thismethod was
used todetectandquantify fluoranthene (FA) adducts inthe rat
(2). FA, likeotherpolycyclic aromatichydrocarbons (PAH), is
generally produced as aresultofincompletepyrolysisoforganic
material, resulting in widespread environmental exposure to
complex mixtures of PAH. Therefore, application of the
HPLC-32P-posflabeling methodinstudiesformonitoring human
exposure to PAH requires chromatographic separation and
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quantitative recoveryofmultiple32P-labeledPAHadducts inone
sample. Inrecentstudies,theHPLC 32P-postlabelingprocedure
hasbeenextendedforthedetectionofmultiplePAHadducts. We
chosetoestablishdetectionmethodsforbenzo[a]pyrene (BaP),
chrysene (CH) andbenz(a)anthracene (BA) diol epoxide (DE)
adducts, becausetheseadducts, aswellasothers, cross-reactin
a widely applied immunoassay (3-5). Thus, the postlabeling
method described herein would be complementary to that
immunosssay.
Methods and Results
The HPLC-32P-Postlabeling Procedure for FA
Adducts
TheHPLC-32P-postlabeling methodfirstdevelopedforquan-
tativeanalysisofFAadducts (1) isoutlined inFigure 1. Briefly,
carcinogen-modified DNA is hydrolyzed enzymatically with
micrococcal nucleaseandspleenphosphodieterasetonucleotide
3'-monophosphate adductsandnucleotide 3'-monophosphates.
Adducts areseparatedfromunmodifiednucleotidesbyapplica-
tionofthehydrolysatetoadisposableC18cartridge. Morethan
99% oftheunmodified nucleotides are removed in an aqueous
wash, and adducts areeluted with methanol (data not shown).
Completeremoval ofunmodified nucleotides isessential for
reproduciblequantification ofFADE adducts by postlabeling.GORELICKANDREEDER
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HPLC-32P-Postlabeling Assay for Detection of
BPDE, BADE, andCHDEAdducts
Attempts to analyzeDNAmodifiedin vitrowithdiolepoxides
of BP, BA, or CH (Fig. 2) by the HPLC-32P- postlabeling
methodexactly aspreviouslydescribed (1) i.e., withnucleaseP1
pretreatment for 15 minandnucleaseP1 post-treatment for 16-18
hr, were unsuccessful; "P-labeled adducts were not detected
(datanotshown). Becausethe cornerstoneofthis method isthe
balancebetweenadductresistance tobriefnucleaseP1-mediated
dephosphorylationandadductsuceptibility toextensivenuclease
P1-mediateddephosphorylation, the sensitivity ofeachofthese
PAH diol epoxide adducts to nuclease P1-mediated
dephosphorylation wasinvestigated.
Chromatographicprofilesofa"P-labeled adductsandthe ap-
propriateultravioletmarkers areshowninFigure 3. Ineach case,
a major 32p peak co-eluted with the appropriate authentic
nucleotide 5 '-monophosphate adduct. Noqualitative difference
wasobservedin anyofthechromatographicprofilesassociated
witheithernuclease P1 pretreatment orthedurationofnuclease
P1 post-treatment (data not shown).
The effect of nuclease P1 pretreatment on recovery of 32p_
labeledadducts wasdetermined. Theimprovement in recovery
ofBPDE, BADE, andCHDEadductsby inclusionofa 10-min
nucleaseP1 pretreatment step is indicated recoveryimprovedby
at least 6-fold as much as 20-fold (BPDE). Analyses for 32p
FIGURE 1. The high-performance liquid chromatography (HPLC)-32P-
postlabeling procedure for detection of radiolabeled nucleotide 5'-
monophosphate adducts. X and Y represent nodified nucleosides. Modified
from Gorelick and Wogan (1).
Thus, to eliminate the residual nucleotides as substrates in the
labelingreaction, the3'-phosphatemoietyisselectively removed
from unmodified nucleotides by a brief(15-30 min) digestion
with nucleaseP1 immediatelypriortopostlabeling. Thisstepon-
ly minimally affects recovery ofFADE adducts (1).
Transferofthe3"P-label from[_y-32P]ATP tothe5'-hydroxyl
positionofadductsismediatedby T4polynucleotidekinase, pro-
ducing 3'-[5' -32P]bisphosphates. Reverse-phase HPLC is
employed toexploitthehydrophobicityofFAHadductsandthus
to separate the multiple adducts that may be found in one sam-
ple. Conversiontonucleotide [5'-32P]monophosophates, which
improves reverse- phase HPLC separation of adducts, is ac-
complishedbyprolongedtreatment, with nucleaseP1, towhich
FADE adducts are sensitive. Finally, adducts are separated by
reverse-phase HPLC, andadductlevelsaredeterminedbyliquid
scintillationcounting.
Each step inthisprocedure wasoptimizedpreviousiy forthe
detectionofFADEadducts(I); themostimportantrequirement
tomaximizerecoveryoflabeledadductswascompleteseparation
ofnormal andmodifiednucleotidespriortopostlabeling. Most
ofthestepsinwhichFAadductlossoccurshavebeenidentified (I).
Overallrecoveryisexpectedtobe 15-35%oftheDNA-boundFA
atmodificationlevelsofoneadductin106-107nucleotides. Since
10-15% oftheinitialDNA-boundFAisactuallyrecovered, loss
ofatmost25% oftheDNA-boundFAisunassigned.
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FIGURE 2. Structures of the polycyclic aromatic hydrocarbon diol epoxide
metabolites reacted withDNA. Themajoradduct foreachmetabolite isan
N2-guanine adduct. Relative stereochemistry is shown.
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FIGURE 3. Chromatographic profiles of"P-labeled adducts fromDNA modifiedwith fluoranthene (FADE), benzo[a]pyrene (BPDE), chrysene (CHDE), and
benz(a)anthracene (BADE)diolepoxides in vitro. Adductswerepostlabeled witha 1-minnucleaseP1 pretreatmentand2.5-hrnucleaseP1 post-treatment. One-third
ofeach sample (18.4 uL) was mixed withanappropriate amountofthecorresponding unlabelednucleotide5'-monophosphateadduct(forultravioletmarker)and
injected viaaWISP Model 715autoinjector(WatersAssociates). Chromatographic separationonapBondapakC18column[3.9mm (ID) x30cm, WatersAssociates]
at room temperature was facilitated by the followinggradient (I mL/min). Isocraticelution with solvent A for20minpreceded alineargradient over 10 min to
20% solvent Bandalineargradientfrom20% to60% Bover45min. Flowwasheldat60% Bfor 10minpriorto25-minequilibration intheinitial solvent. Sol-
vent A: 10% methanol in0.1 Mammonium acetate, I mM ammonium dihydrogenphosphate, pH5.7; solventB: methanol. Radioactivity wasdetectedon-line
witheithera Model A140Or Model A280detector (Radiomatic InstrumentsandChemical Co, Inc., Meriden, CT) equipped with a0.5-mL liquid flow cell, at
3 mL/min Flo-Scint IV.
labeled unmodified nucleotides showedthata 10-min nuclease
P1 pretreatment stepisindicated inTable 1. Adductrecovery im-
proved by at least 6-fold (BADE) and as much as 20-fold
(BPDE). Analyses for32P-labeleduniodifiednucleotidesshow-
ed that a 10-min nuclease P1 pretreatment is sufficient to
dephosphorylate residual unmodified nucleotides (data not
shown).
Figure4showsthedependenceof32P-labeledadductrecovery
onthelengthofnucleaseP1 post-treatment. Althoughprolonged
Thble 1. Effectofnuclease P1 pretreatment on
recoveryof32P-labeled adducts.a
32P-labeled adduct, fmolec
Pretreatment b BPDE CHDE BADE
No nuclease PI 49± 9 49± 5 ND
Nuclease P1 313 ±70 468±89 43± 4
Abbreviations: BPDE, benzolaJpyrene diol epoxide; CH, chrysene; BADE,
benz[aJanthracene diol epoxide; ND, nonedetected (limitofdetection wasap-
proximately 0.4 fmoleadduct).
aAll samples were also treated with nuclease P1 for 30 min after labeling.
Average ± SD for three to foursamples.
bFor 10 minwith 12.5,tg nucleaseP1 or water.
hydrolysis withnucleaseP1 isrequiredformaximal recoveryof
FADE adducts (12-18 hr) (1), maximal recovery ofBPDE and
CHDEadductsoccursafterlessthan30-minnucleaseP1 post-
treatment, andmaximalrecoveryofBADEadductsoccursafter
1-2hrpost-treatment. Thus, BPDE, CHDE, andBADEadducts
arelessresistanttonucleaseP1-mediateddephosphorylationthan
FADE adducts.
Todeterminetherecoveryof"P-labeledBPDEadductsinthe
HPLC-32P-postlabeling procedure, increasing amounts of
[3H]BP-modified DNA were mixed with carrier DNA (calf
thymus) to comprise samples of 15,g DNA. Recovery of32P-
labeledBaPDEadductwaslinearforDNAsamplescontaining
20-660 fmole BaPadduct [r = 0.876(Fig. 5)]. Recovered 32P-
labeled BPDE adducts constituted about 10% ofthe original
DNA-boundBaP; thus,approximately 12% oftheBPDEadducts
originallyintheDNAwererecoveredbypostlabeling. Lossesof
BPDEadductshavenotbeenassignedtoparticular steps inthe
postlabelingprocedure; however, nonspecificlossesduetosam-
plemanipulation arelikely, asinthecaseofFADEadducts. Ad-
duct recovery iscurrently being improved.
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i'tm' 1.1 j> = recovery of 32P-labeled BaP-diol epoxide (BPDE) adducts. DNA was o\ fl l_J = modifiedin vitro with[3H]BaPasdescribedbyDankovicetal. (6), whereby
the major adduct co-eluted withthe (+) anti-diol epoxide adduct ofdeox- ~. 1000 yguanosine and accounted for approximately 80% of the total bound
metabolites. Increasing amountsof[3HIBaP-modified DNAwere mixedwith
calfthymusDNA, and 15 g DNAsamples werepostlabeledwitha 10-min
Q) \nucleaseP1 pretreatmentand a 30-minnuclease P1 post-treatment. Duplicate C.) 500 ortriplicatesamples wereanalyzedtwice.Averageand range arepresented.
r,__ The equation ofthe regression line isy = 0.094x + 5.4.
C\ F 1\1 l
\ ___________ foradductdetectionandquantification. Theadvantagesforad-
d_____________________ _ 'duct separation include speed of analysis, reproducible and
characteristicretention,quantificationoflowadductlevelsbyon-
B A D E lineanalysisofradioactivityforminimalhumanexposureto 32p,
the easewithwhich asamplecanberecoveredafterseparation,
1000 and the possibility ofcoupling HPLC separation with various
otherdetectionmethods, such as massspectrometry, which can
provideadditional structural information. Reverse-phaseHPLC
hasbeenusedforanalyzingpostlabeled aromatic (9; thiswork)
500 ; \ aswell asalkyl (10,11)nucleotidemonphosphateadducts. Alter- Soo Tnatively, ion-pair HPLCcanbeusedforanalyzingpostlabeled
-,__- bulky nucleotidebisphosphate adducts (12,13).
Themostsensitiveversionsofthepostlabelingassay include
.-I ....... ...... .. ... asteptoseparatemodifiedandunmodified nucleotidespriorto
0 1 2 3 4 5 6 7 labeling;alternativeversionsofthepostlabeling method involv-
ing different techniques. Nuclease P1 treatment ofhydrolyzed
NUCLEASE P 1 POST- TREATMENT(hrDNA(withoutintialchromatographicseparation)before label-
NUCLEASE P1 POST-TREATMENT(hr) ing is applicable for selected adducts (14), whereasbutanol ex-
tractionisanefficientmethodforisolatingotherselected adducts
FIGURE 4. Timecourse fornuclease P1 treatmentafter32P-labeling ofben- (15,16). Adduct enrichment by HPLC fractionation is advan-
zolalpyrene diol epoxide (BPDE)-DNA, chrysenediol epoxide(CHDE)- tageousinthattheyieldofnucleotidesactually inthesamplecan
DNA, and benz[aIanthracene diol epoxide (BADE)-DNA. Each diol be measured and the relative adductlevel in the sample can be
epoxide-modified DNA (I pg) wasmixedwithcalfthymus DNA(14,sg) and
postlabeled witha 10-min nuclease PI pretreatment as described (1). The calculated (17-20). Immunoaffinity chromatography may be
meanand rangeforduplicatesamples are indicated. usefulforisolatingadducts, althoughitsapplicationislimitedby
solvent incompatibilities (21) and antibody availability. The
Discussion resultsdescribedaboveshowthevalueofcombiningofmethods
forcompleteelimination ofunmodified nucleotides.
Many versions of the 3"P-postlabeling assay have been BPDE,BADE, andCHDEadducts aresignificantly moresen-
developed todetect adducts ofknown and unknown structure; sitive todephosphorylation by nuclease P1 than are FADE ad-
most of these involve thin-layer chromatography for adduct ducts. Similardifferencesinsensitivity tonucleaseP1 hasbeen
separation (Z,8). Thetime-consuming, labor-intensive natureof observed with other classes of adducts, e.g., arylamine-
thin-layer chromatography, and the fact that quantitative C8-guanine adducts (16). It is notablethat adducts ofthe same
estimatesofadduct recovery afterthisprocedurehavenotbeen chemical and nucleotide class, i.e., PAH diol epoxide-N2-
determined rigorously, limits its application in molecular guanineadducts, varywidely intheirsensitivity tonucleaseP1.
epidemiology studies. Theseresultsunderscorethefactthatthebalancebetweenadduct
CouplingpostlabelingwithHPLCofferstechnicaladvantages resistance to brief nuclease P1 pretreatment and prolonged
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nuclease P1 post-treatment mustbeexamined foreach adduct.
A battery ofpostlabeling assays may make itpossible to detect
optimally multiple adducts inone DNA sample. Alternatively,
determination ofthe recovery of multiple adducts under par-
ticular conditions will enable quantitative analysis, albeit
sometimes with less thanoptimal detection.
ApplicationoftheHPLC-32P-postlabeling methodtoanalysis
of adducts in human tissues requires the ability to detect and
quantify simultaneously multiple adducts, oftenfromthe same
chemical class. Thus, we undertook to optimize this sensitive
method for the detectionofmultiple PAH adductsas well as to
determine the quantitative recovery ofeach adduct in this pro-
cedure. Our results indicate that documentation of the quan-
titativepowerofthisassay isessentialforaccurateinterpretation
ofadduct levels determined in human samples.
This manuscript was presented asaposterattheConferenceon Biomonitor-
ing and Susceptibility Markers in Human Cancer: Applications in Molecular
Epidemiology and Risk Assessment that was held in Kailua-Kona, Hawaii, 26
October-l November 1991.
We thank David Springer for the generous giftof[3H]BaP-DNA.
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